celon

02PDE2019
Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore Efficacy, safety and pharmacokinetics of CPL500036 (PDE10a inhibitor) in Patients With an Acute Exacerbation of Schizophrenia

Dear Sir or Madam

We would like to invite you to participate in the study named: " Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore Efficacy, safety and pharmacokinetics of CPL500036 (PDE10a inhibitor) in Patients With an Acute Exacerbation of Schizophrenia".

Schizophrenia is a mental disorder seriously impairing the ability to think logically, establish relationships with people and functioning in society.

This disease affects about 1% of the population with the onset of morbidity at the age of 20 to 30 years. It is characterized by many symptoms, which in each patient can develop in a completely different direction and occur with various intensities.

Celon Pharma’s product PG20, with CPL500036 as an active ingredient is designed predominantly for the treatment of psychotic disorders like schizophrenia.

The main study goal is to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia when administered for 28 days.

Clinical trial results will be used to further development of new oral drug used in psychiatry.

celon

eCRF i Data Management

+48 666 069 834
support@biostat.com.pl

BioStat is responsible for eCRF development, data management and statistical service.

biostat